AstraZeneca teams up with Inovio Pharmaceuticals
Under the terms of the deal, AstraZeneca's biological research and development arm MedImmune will acquire exclusive rights to Inovio’s INO-3112 immunotherapy,
Continue Reading
Under the terms of the deal, AstraZeneca's biological research and development arm MedImmune will acquire exclusive rights to Inovio’s INO-3112 immunotherapy,
Continue Reading
Join the Discussion